Sarah Alexandra Schäfer1, Carolin Hülsewig2, Peter Barth3, Marie-Kristin von Wahlde4, Joke Tio4, Hans-Christian Kolberg5, Christof Bernemann6, Jens-Uwe Blohmer7, Ludwig Kiesel4, Cornelia Kolberg-Liedtke7. 1. Department of Pediatrics, Sana Kliniken Duisburg, Zu den Rehwiesen 9, 47055 Duisburg, Germany. 2. Molecular Health GmbH, Kurfürstenanlage 21, 69115 Heidelberg, Germany. 3. Gerhard-Domagk Departement for Pathology, University Münster, Albert-Schweitzer Campus 1 D17, 48149 Münster, Germany. 4. Department of Gynecology & Obstetrics, University Hospital Münster, Albert-Schweitzer Campus 1 A1, 48149 Münster, Germany. 5. Department of Gynecology & Obstetrics, Marienhospital Bottrop, Josef-Albers-Str. 70, 46236 Bottrop, Germany. 6. Department of Urology, University Hospital Münster, Albert-Schweitzer Campus 1 A1, University Münster, Medical Faculty, Domagkstr, 48149 Münster, Germany. 7. Department of Gynecology & Breast Center, Charité University Hospital Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Abstract
Aim: Breast cancer is a heterogeneous disease with distinct molecular and clinical behavior demanding reliable biomarkers, especially in triple-negative breast cancer (TNBC). This study seeks to improve the understanding of SFRP1 as a potential biomarker in breast cancer focusing on TNBC. Materials & methods: SFRP1 expression was investigated via immunohistochemistry with two anti-SFRP1-antibodies on tissue-microarrays of 376 invasive breast cancers. Results: Statistical analysis revealed a highly significant association between TNBC (n = 36) and SFRP1 expression (p < 0.001). SFRP1 expression was significantly associated with younger age, higher tumor stage, size and grade. Conclusion: SFRP1 expression is strongly correlated with TNBC on protein level. Associations with age and tumor grade support the role of SFRP1 as a biomarker for chemotherapy response in TNBC.
Aim: Breast cancer is a heterogeneous disease with distinct molecular and clinical behavior demanding reliable biomarkers, especially in triple-negative breast cancer (TNBC). This study seeks to improve the understanding of SFRP1 as a potential biomarker in breast cancer focusing on TNBC. Materials & methods: SFRP1 expression was investigated via immunohistochemistry with two anti-SFRP1-antibodies on tissue-microarrays of 376 invasive breast cancers. Results: Statistical analysis revealed a highly significant association between TNBC (n = 36) and SFRP1 expression (p < 0.001). SFRP1 expression was significantly associated with younger age, higher tumor stage, size and grade. Conclusion:SFRP1 expression is strongly correlated with TNBC on protein level. Associations with age and tumor grade support the role of SFRP1 as a biomarker for chemotherapy response in TNBC.
Entities:
Keywords:
SFRP1; biomarker; chemotherapy; tissue microarray; triple-negative breast cancer